Does anyone know why Ibrutinib is only available to CLL patients whose previous treatments have been unsuccessful?
It was first made routinely available to leukaemia patients through the NHS in 2016, apparently after years of campaigning by Bloodwise, the cancer research charity.
I've read posts on here which seem to claim that the new immunotherapies such as Ibrutinib have a better outcome when used as a first treatment, instead of FCR.
Also that the residual toxiticies of FCR, negatively affect ibrutinib.
I believe it's a particularly expensive drug, so maybe it's the NHS trying to save money?